Q-omics provides the consensus-scored CLDN4 profile across patient tissues and cancer cell-line models. CLDN4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLDN4 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CLDN4 RNA expression shows 18,177 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where CLDN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN4 survival associations across molecular data types. CLDN4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN4 RNA expression–survival associations across cancer types. High CLDN4 expression shows unfavorable associations in PAAD, LGG, MESO, OV and ESCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLDN4 RNA expression.
This table summarizes CLDN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CLDN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN4 shows lower tumor expression in KIRC, HNSC and KICH and higher tumor expression in LUAD, STAD and THCA. The LUAD box plot shows higher CLDN4 RNA expression in tumor versus normal tissue (log2 FC = +1.557, t-test p < 0.001).
This table shows molecular features associated with CLDN4 in patient tissues and cancer cell lines. In patient samples, CLDN4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
